Oppenheimer Reiterates Buy Rating on Corbus Pharmaceuticals

Oppenheimer has reaffirmed its buy rating for Corbus Pharmaceuticals Holdings, Inc. (NasdaqCM: CRBP) as of June 17, 2026. The firm set a price target of $52, indicating confidence in the biotech company's potential.

Other Institutional Activity in Corbus Pharmaceuticals

CORMORANT ASSET MANAGEMENT, LP holds 2,344,971 shares valued at approximately $22.02 million, with no change in its position. ORBIMED ADVISORS LLC increased its stake by 140,000 shares, bringing its total to 1,737,287 shares worth about $16.31 million. VANGUARD CAPITAL MANAGEMENT LLC initiated a new position with 734,106 shares valued at around $6.89 million. Meanwhile, CITADEL ADVISORS LLC reduced its holdings by 116,133 shares, ending with 727,060 shares valued at approximately $6.83 million.

Corbus Pharmaceuticals Holdings, Inc. Stock Up 2.6%

Shares of NasdaqCM:CRBP are trading near $7.88. The company has a market cap of $151.7 million and a high beta of 2.59, indicating higher volatility compared to the market. Its 52-week trading range is between $6.72 and $20.56. The stock's 50-day moving average is $9.72, while the 200-day moving average is $10.27. Corbus Pharmaceuticals has a current ratio of 7.92, a quick ratio of 7.70, and a debt-to-equity ratio of 0.95.

Recent Earnings

Corbus Pharmaceuticals, not currently profitable, reported a negative EPS of -$5.74. The company has no meaningful P/E ratio. Its return on equity stands at -66.7%, reflecting its ongoing development phase. The next earnings report is expected on May 12, 2026.

Insider Buying and Selling at Corbus Pharmaceuticals Holdings, Inc.

Recent insider activity includes several planned sales on June 10, 2026, by individuals such as John Kenneth Jenkins and Winston Kung, each selling shares at an average price of $7.91. Notably, Chief Business Officer Nishant Saxena purchased shares on multiple occasions, including 9,000 shares at $7.58 on June 3, 2026, and 4,500 shares at $7.33 on June 2, 2026.

Analysts Set New Price Targets

On June 17, 2026, Oppenheimer maintained its buy rating on Corbus Pharmaceuticals with a $52 price target. Wedbush also maintained a buy rating with a $30 target on May 27, 2026. HC Wainwright & Co. reiterated a buy rating with a $40 target on May 26, 2026. The consensus among analysts is a strong buy, with a mean target price of $36.50 based on 10 analyst opinions.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., headquartered in Norwood, Massachusetts, is a clinical-stage biotech company focused on developing treatments for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate targeting cancer cells, and CRB-913, aimed at treating obesity by modulating cannabinoid receptors. The company operates in the healthcare sector within the biotechnology industry and employs 36 people under the leadership of CEO Dr. Yuval Cohen.

Bottom Line

Oppenheimer's reiteration of a buy rating and a $52 target for Corbus Pharmaceuticals suggests continued optimism about the company's future prospects. While the stock trades at $7.88, its volatile nature, reflected by a high beta, might interest investors tracking the biotech sector. As always, remember that analyst ratings and 13F filings look backward and may not reflect the latest market conditions.